ANTITUMOR ACTIVITY OF NAB-PACLITAXEL AND BEVACIZUMAB AGAINST A NEW TRIPLE NEGATIVE BREAST CANCER MODEL

被引：0
|
作者：
Trieu, V. [1 ]
Blackwell, K. L. [2 ]
Volk, L. [2 ]
Wilber, A. [2 ]
Desai, N. [1 ]
机构：
[1] Abraxis BioSci, Randd, Los Angeles, CA USA
[2] So Illinois Univ, Sch Med, Springfield, IL USA
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：43 / 43
页数：1
相关论文
共 50 条
  • [41] Carboplatin, nab-paclitaxel and bevacizumab as first-line treatment for metastatic breast cancer.
    Lo, S. S.
    Guo, R.
    Czaplicki, K. L.
    Robinson, P. A.
    Gaynor, E.
    Barhamand, F. B.
    Schulz, W. C.
    Kash, J. J.
    Horvath, L. E.
    Bayer, R. A.
    Petrowsky, C.
    De la Torre, R.
    Park, J. H.
    Albain, K. S.
    CANCER RESEARCH, 2012, 72
  • [42] Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial
    Jiang, Zefei
    Ouyang, Quchang
    Sun, Tao
    Zhang, Qingyuan
    Teng, Yuee
    Cui, Jiuwei
    Wang, Haibo
    Yin, Yongmei
    Wang, Xiaojia
    Zhou, Xin
    Wang, Yongsheng
    Sun, Gang
    Wang, Jingfen
    Zhang, Lili
    Yang, Jin
    Qian, Jun
    Yan, Min
    Liu, Xinlan
    Yi, Tienan
    Cheng, Ying
    Li, Man
    Zang, Aimin
    Wang, Shusen
    Wang, Chuan
    Wu, Xinhong
    Cheng, Jing
    Li, Hui
    Lin, Ying
    Geng, Cuizhi
    Gu, Kangsheng
    Xie, Chunwei
    Xiong, Huihua
    Wu, Xiaohong
    Yang, Junlan
    Li, Qingshan
    Chen, Yiding
    Li, Fanfan
    Zhang, Anqin
    Zhang, Yongqiang
    Wu, Yudong
    Nie, Jianyun
    Liu, Qiang
    Wang, Kun
    Mo, Xueli
    Chen, Lilin
    Pan, Yueyin
    Fu, Peifen
    Zhang, Helong
    Pang, Danmei
    Sheng, Yuan
    NATURE MEDICINE, 2024, 30 (02) : 249 - 256
  • [43] Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study
    Emens, Leisha A.
    Molinero, Luciana
    Loi, Sherene
    Rugo, Hope S.
    Schneeweiss, Andreas
    Dieras, Veronique
    Iwata, Hiroji
    Barrios, Carlos H.
    Nechaeva, Marina
    Anh Nguyen-Duc
    Chui, Stephen Y.
    Husain, Amreen
    Winer, Eric P.
    Adams, Sylvia
    Schmid, Peter
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2021, 113 (08): : 1005 - 1016
  • [44] Cost-effectiveness analysis of atezolizumab plus nab-paclitaxel for untreated metastatic triple-negative breast cancer
    Li, Jiahao
    Zhang, Tiantian
    Lu, Peiyao
    Zhao, Jianfu
    Chen, Lin
    Jiang, Jie
    IMMUNOTHERAPY, 2020, 12 (10) : 705 - 713
  • [45] Mechanisms of action and acquired resistance to atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer (mTNBC).
    Molinero, Luciana
    Emens, Leisha A.
    Goldstein, Leonard D.
    Abbas, Alexander R.
    Koeppen, Hartmut
    Rugo, Hope S.
    Adams, Sylvia
    Chui, Stephen Y.
    Schmid, Peter
    Loi, Sherene
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [46] Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial
    Zefei Jiang
    Quchang Ouyang
    Tao Sun
    Qingyuan Zhang
    Yuee Teng
    Jiuwei Cui
    Haibo Wang
    Yongmei Yin
    Xiaojia Wang
    Xin Zhou
    Yongsheng Wang
    Gang Sun
    Jingfen Wang
    Lili Zhang
    Jin Yang
    Jun Qian
    Min Yan
    Xinlan Liu
    Tienan Yi
    Ying Cheng
    Man Li
    Aimin Zang
    Shusen Wang
    Chuan Wang
    Xinhong Wu
    Jing Cheng
    Hui Li
    Ying Lin
    Cuizhi Geng
    Kangsheng Gu
    Chunwei Xie
    Huihua Xiong
    Xiaohong Wu
    Junlan Yang
    Qingshan Li
    Yiding Chen
    Fanfan Li
    Anqin Zhang
    Yongqiang Zhang
    Yudong Wu
    Jianyun Nie
    Qiang Liu
    Kun Wang
    Xueli Mo
    Lilin Chen
    Yueyin Pan
    Peifen Fu
    Helong Zhang
    Danmei Pang
    Yuan Sheng
    Nature Medicine, 2024, 30 : 249 - 256
  • [47] Pilot study of carboplatin, nab-paclitaxel and pembrolizumab for metastatic triple-negative breast cancer (ongoing clinical trial)
    Baar, J.
    Abraham, J.
    Silverman, P.
    Budd, G. T.
    Vinayak, S.
    Varadan, V.
    Moore, H.
    Montero, A.
    Fu, P.
    CANCER RESEARCH, 2017, 77
  • [48] Safety and clinical activity of atezolizumab (anti-PDL1) in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer
    Adams, S.
    Diamond, J.
    Hamilton, E.
    Pohlmann, P.
    Tolaney, S.
    Molinero, L.
    Zou, W.
    Liu, B.
    Waterkamp, D.
    Funke, R.
    Powderly, J.
    CANCER RESEARCH, 2016, 76
  • [49] nab-Paclitaxel for the Treatment of Aggressive Metastatic Breast Cancer
    Glueck, Stefan
    CLINICAL BREAST CANCER, 2014, 14 (04) : 221 - 227
  • [50] SPARC microeniironment signature (SNIP) in patients treated with nab-paclitaxel (nabP)/carboplatin (C)/bevacizumab(B) for triple-negative e metastatic breast cancer (TNMBC).
    Blackwell, K. L.
    Hamilton, E. P.
    Rocha, G.
    Gainey, M.
    Trieu, V. N.
    Motamed, K.
    Pramanik, P.
    Hwang, L.
    Treece, T.
    Desai, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345